Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

LGND 52.04 +0.08 (0.15%)
price chart
Ligand Pharmaceuticals Inc Stock Downgraded (LGND)
LIGAND PHARMACEUTICAL INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago.
Ligand Pharmaceuticals Inc. (LGND) Largest Owner Sells Shares
Raising prospects for a continued deterioration in the stock price of Ligand Pharmaceuticals Inc. (NASDAQ:LGND), the largest shareholder in the company has moved to unload shares of the troubled company in a private transactions.
Related articles »  
Ligand Pharmaceuticals, Inc. (LGND) Tops Q2 EPS by 10c; Boosts FY14 Outlook
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q2 EPS of $0.24, $0.10 better than the analyst estimate of $0.14.
Ligand Pharmaceuticals Inc. (LGND) Issues FY14 Earnings Guidance  Watch List News (press release)
Ligand Reports Second Quarter 2014 Financial Results  Wall Street Journal
Related articles »  
Ligand Pharmaceuticals Inc.: Ligand Signs Multi-Program Captisol� License ...
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a commercial license agreement with Avion Pharmaceuticals, LLC for the development and commercialization of four Captisol-enabled ...
Lemelson: Ligand Pharmaceuticals At Risk Of Bankruptcy  ValueWalk
Ligand Pharma Inks Deal With Avion To Develop Captisol-enabled Programs  RTT News
Related articles »  
Stocks in the Spotlight: Ligand Pharmaceuticals Inc. (LGND), Walgreen ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) jumped more than 11 percent today after the biotechnology company reported a profit of $0.24 per share for the second quarter that topped consensus forecast of $0.14 per share.
Today's Hot List: 22nd Century Group, Inc. (NYSEMKT:XXII), Ligand ...
During the same quarter in the previous year, the company posted $0.07 earnings per share. The company's revenue for the quarter was up 10.4% on a year-over-year basis.
Related articles »  
Zacks Downgrades Ligand Pharmaceuticals to Underperform (LGND)
Ligand Pharmaceuticals Inc. logo Zacks lowered shares of Ligand Pharmaceuticals (NASDAQ:LGND) from a neutral rating to an underperform rating in a research report released on Thursday morning.
Ligand Pharmaceuticals Downgraded by Zacks to "Underperform" (LGND)  Watch List News (press release)
Exclusive: Emmanuel Lemelson Talks Ligand Pharmaceuticals  Benzinga
Related articles »  
Ligand Pharmaceuticals Rating Lowered to Underperform at Zacks (LGND)
Ligand Pharmaceuticals Inc. logo Ligand Pharmaceuticals (NASDAQ:LGND) was downgraded by Zacks from a �neutral� rating to an �underperform� rating in a report issued on Thursday.
Ligand Pharmaceuticals Given Average Rating of "Hold" by Analysts ...  Watch List News (press release)
Related articles »  
Lemelson Capital Comments on Large Institutional Selling in Shares of Ligand ...
25, 2014 /PRNewswire/ -- Lemelson Capital Management, a private investment management firm, today released additional research and comments on Ligand Pharmaceuticals LGND, +0.15% amidst the company's unusual and complex debt arrangement ...
Related articles »  
Investors Watch List : Johnson & Johnson (NYSE:JNJ), Ligand Pharmaceuticals ...
Following the completion of the acquisition, the chief executive officer now directly owns 120,099 shares of the company's stock, valued at approximately $6,601,842. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) traded 139657 shares and its share ...